Jonathan Lim
Providence College(US)Children's Hospital Colorado(US)GlaxoSmithKline (United States)(US)University of Colorado Anschutz Medical Campus(US)University of Colorado Denver(US)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Atrial Fibrillation Management and Outcomes, Lung Cancer Treatments and Mutations, Health Systems, Economic Evaluations, Quality of Life
Most-Cited Works
- → Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer(2015)245 cited
- → STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.(2015)47 cited
- → Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States(2016)32 cited
- → Impact of Evidence‐Based Stroke Care on Patient Outcomes: A Multilevel Analysis of an International Study(2019)27 cited
- → Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain – results of a Delphi Panel(2016)26 cited
- → Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups